Clinical trials testing anti-PD1 or anti-PDL1 drugs to restore anti-cancer immunity have shown very promising results with durable responses, notably in melanoma and renal, lung, prostate and bladder carcinomas [16-18], and phase III studies are ongoing. This evidence concerns the gene CD274 and cancer.